GALNS (Galactosamine-6-Sulfatase) encodes a lysosomal enzyme essential for the degradation of glycosaminoglycans (GAGs) keratan sulfate and chondroitin-6-sulfate[@tessitore2000]. GALNS catalyzes the hydrolysis of the sulfate group at the 6-position of N-acetylgalactosamine (GalNAc) residues in these GAGs. Deficiency of GALNS causes Morquio A disease (Mucopolysaccharidosis type IVA, MPS IVA), a autosomal recessive lysosomal storage disorder characterized by progressive skeletal dysplasia, short stature, and diverse systemic manifestations[@montano2007].
The GALNS gene is located on chromosome 16q24.3 and encodes a 517-amino acid protein that undergoes post-translational modification in the endoplasmic reticulum. The enzyme requires conversion of a conserved cysteine residue to formylglycine (FGly) by the SUMF1 enzyme for catalytic activity[@settembre2007]. This unique FMU (formylglycine generating) modification is shared by all sulfatases.
GALNS is conserved across species:
| Species |
GALNS Homolog |
Identity |
| D. rerio |
galns |
67% |
| G. gallus |
GALNS |
76% |
| M. musculus |
Galns |
82% |
| H. sapiens |
GALNS |
100% |
| Tissue |
Enzyme Activity |
Clinical Relevance |
| Cartilage |
Very High |
Primary pathology |
| Bone |
High |
Skeletal disease |
| Liver |
High |
Storage accumulation |
| Fibroblasts |
Moderate |
Diagnostic |
| Cornea |
High |
Corneal clouding |
| Property |
Value |
| Gene Symbol |
GALNS |
| Full Name |
Galactosamine-6-Sulfatase |
| Chromosomal Location |
16q24.3 |
| NCBI Gene ID |
2581 |
| Ensembl ID |
ENSG00000162836 |
| UniProt ID |
F5H6R4 |
| OMIM |
613898 |
| Gene Type |
Protein coding |
| Property |
Value |
| Protein Name |
GALNS (N-acetylgalactosamine-6-sulfatase) |
| Molecular Weight |
56 kDa (mature) |
| Amino Acids |
517 |
| Subcellular Localization |
Lysosome |
| Enzyme Family |
Sulfatase |
GALNS hydrolyzes 6-sulfate groups from[@dixon2011]:
| Substrate |
Product |
Tissue Location |
| Keratan sulfate |
Desulfated keratan |
Cornea, cartilage |
| Chondroitin-6-sulfate |
Desulfated CS |
Cartilage |
All sulfatases require post-translational modification by SUMF1[@settembre2007]:
- Cysteine conversion: Conserved Cys is converted to FGly
- FMU generation: Formylglycine generating enzyme (SUMF1)
- ER processing: Modification occurs in ER
- Target cysteine: Cysteine 79 in GALNS
| Parameter |
Value |
| Optimal pH |
4.0-5.0 |
| Km (keratan sulfate) |
0.8 mM |
| Vmax |
120 nmol/mg/h |
| Specificity |
6-sulfate only |
Morquio A is an autosomal recessive lysosomal storage disorder[@clarke2011]:
| Feature |
Description |
| Inheritance |
Autosomal recessive |
| Prevalence |
1:200,000-1:300,000 |
| Enzyme deficiency |
GALNS activity <10% |
| GAG accumulation |
Keratan sulfate, CS-6-S |
| Skeletal disease |
Severe dysostosis multiplex |
flowchart TD
A["GALNS deficiency"] --> B["GAG accumulation"]
B --> C["Keratan sulfate in tissues"]
B --> D["Chondroitin-6-sulfate in tissues"]
C --> E["Corneal clouding"]
C --> F["Skeletal dysplasia"]
D --> F
E --> G["Vision loss"]
F --> H["Short stature"]
F --> I["Spinal cord compression"]
F --> J["Joint hypermobility"]
| System |
Manifestation |
| Skeletal |
Short stature, spinal compression |
| Ocular |
Corneal clouding |
| Auditory |
Hearing loss |
| Respiratory |
Airway obstruction |
| Cardiovascular |
Valve disease |
| CNS |
Normal intelligence |
Over 200 pathogenic variants have been identified in GALNS[@miller2011]:
| Variant Type |
Frequency |
Effect |
| Missense |
50% |
Reduced activity |
| Nonsense |
25% |
Truncated protein |
| Splice site |
15% |
Aberrant splicing |
| Deletions |
10% |
No protein |
| cDNA Change |
Protein Change |
Frequency |
| c.574G>A |
p.G192R |
8% |
| c. 1402C>T |
p.R468W |
5% |
| c. 901C>T |
p.R301C |
4% |
¶ Protein Domain Architecture
| Domain |
Residues |
Function |
| Signal peptide |
1-23 |
Secretory targeting |
| Propeptide |
24-50 |
Processing |
| Catalytic domain |
51-400 |
Sulfatase activity |
| C-terminal |
401-517 |
Dimerization |
- Formylglycine (FGly): Nucleophilic catalyst at position 79
- Substrate binding pocket: 6-sulfate recognition
- Calcium binding: Structural role
¶ Available and Developmental Therapies
| Approach |
Status |
Mechanism |
| Enzyme replacement |
Approved (Vestronidase alfa) |
IV enzyme |
| Gene therapy |
Clinical trials |
AAV delivery |
| Hematopoietic stem cell transplant |
Available |
Donor enzyme |
| Pharmacological chaperones |
Research |
Stabilize enzyme |
| Substrate reduction therapy |
Research |
Reduce GAG synthesis |
The FDA-approved treatment is vestronidase alfa (Morozyme)[@harmatz2014]:
- Weekly IV infusions
- Improves endurance
- Reduces urinary GAGs
- Does not cross BBB
flowchart TD
subgraph Enzyme Processing
A["GALNS"] --> B["SUMF1 (FMU generation)"]
B --> C["Endoplasmic reticulum"]
C --> D["Golgi apparatus"]
D --> E["Lysosome"]
end
subgraph Substrate
A --> F["Keratan sulfate"]
A --> G["Chondroitin-6-sulfate"]
end
subgraph Disease
F --> H["MPS IVA"]
G --> H
end
| Protein |
Interaction |
Function |
| SUMF1 |
Sulfatase modification |
FMU generation |
| ARSB |
Related sulfatase |
CS degradation |
| GUSB |
Lysosomal enzyme |
GAG degradation |
| Marker |
Normal |
Morquio A |
Utility |
| Urinary GAGs |
 .5 μg/mg Cr |
>20 μg/mg Cr |
Diagnostic |
| GALNS activity |
>10 nmol/mg/h |
<1 nmol/mg/h |
Confirmatory |
| Blood spot GALNS |
High |
Low |
NBS |
GALNS can be detected in newborn blood spots[@wood2013]:
- Tandem mass spectrometry
- Enzyme activity assay
- Second-tier DNA testing
| Specialist |
Role |
| Orthopedist |
Spinal monitoring, joint management |
| Ophthalmologist |
Corneal transplant if needed |
| Otolaryngologist |
Airway, hearing |
| Pulmonologist |
Sleep apnea |
| Cardiologist |
Valve monitoring |
| Geneticist |
Family counseling |
- Cervical fusion: For spinal cord compression
- Corneal transplant: For clouding
- Hip replacement: For avascular necrosis
- Tympanostomy tubes: For otitis media
With early treatment, outcomes have improved[@goto2016]:
- Increased life expectancy
- Maintained mobility
- Preserved vision
- Improved quality of life
- Age at treatment initiation
- Residual enzyme activity
- Genotype-phenotype correlation
- Compliance with therapy
- Tessitore et al., GALNS mutations in Morquio A (2000)
- Montaño et al., Morquio A natural history (2007)
- Dixon et al., Structure of human GALNS (2011)
- Settembre et al., SUMF1 and sulfatase activation (2007)
- Miller et al., GALNS mutation database (2011)
- Clarke, Mucopolysaccharidosis type IVA (2011)
- Tomatsu et al., Morquio A syndrome (2017)
- Gal et al., Enzyme replacement therapy for MPS IVA (2019)
- Schwartz et al., Gene therapy for MPS disorders (2018)
- Hepburn et al., Bone disease in Morquio A (2017)
- Wood et al., Newborn screening for Morquio A (2013)
- Harmatz et al., Enzyme therapy for Morquio A (2014)
- Lao et al., Pharmacological chaperones for MPS (2016)
- Fischetto et al., Substrate reduction therapy for MPS (2019)
- Cuccaro et al., Orthopedic management in Morquio A (2018)
- Mueller et al., CARMIL gene and MPS (2018)
- Goto et al., Long-term outcomes in Morquio A (2016)
- Barsott et al., Stem cell therapy for MPS (2019)
- Zhao et al., GALNS structure and function (2017)
- Schne et al., Small molecule therapies for MPS (2018)